A federal consultative group voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is not final. The FDA has given no word on whether it will adopt the suggestion. The move came after weeks of public comment sessions. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could alter how the agency handles a part of the wellness market that is expanding rapidly. Industry players are waiting to see if the agency adopts the plan. A spokesperson for the agency offered no deadline for a follow-up. Critics argue the change would open up access to products that users favor. Safety voices warn that looser rules could allow poor oversight across a quickly growing market. The Thursday vote only clears a path to a change, and the final call rests with the agency.
Sources & References
-
FDA panel recommends loosening restrictions on controversial peptide - The Washington Post
FDA panel recommends loosening restrictions on controversial peptide The Washington Post
-
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition - Time Magazine
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition Time Magazine
-
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week - The American Journal of Managed Care
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week The American Journal of Managed Care
-
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers - AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers AP News
-
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. - MarketWatch
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. MarketWatch